Super-adjuvant nanoparticles are a new type of cancer vaccine that works much better than older versions. Scientists at the University of Massachusetts Amherst created them. Their main study came out in October 2025 in Cell Reports Medicine. These tiny particles fight cancer by waking up the body’s immune system in a smart way. They mix […]
SGLT2 inhibitors, familiar as diabetes medications like dapagliflozin and canagliflozin, show promise against prostate cancer (and other solid tumors) through targeted metabolic disruption that exploits cancer cells’ addiction to glucose. Prostate tumors frequently overexpress SGLT2 transporters, enabling excessive glucose uptake that fuels the Warburg effect, where cancer cells convert glucose to lactate even in oxygen-rich […]
The Japanese tree frog, Dryophytes japonicus, has become the source of a striking experimental cancer approach via a gut bacterium, Ewingella americana, that can completely eradicate colorectal tumors in mice. Amphibians and reptiles rarely develop cancer, so researchers systematically screened 45 bacterial strains from frogs, newts, and lizards; nine showed anti-tumor activity, but E. americana […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! I want to wish you all a Merry Christmas! We’ve almost reached Newsletter number 52, and new trials and research keep coming in. Stay strong and fight on! As usual, we also have a podcast if you prefer to […]
A team of scientists in China has found a way to turn the same type of cells that cause allergies into a new kind of weapon against cancer. Their work suggests that the body’s fastest immune reaction, normally blamed for hives and asthma, could be redirected to wake up the immune system inside tumors and […]
A Phase 3 clinical trial is evaluating Inavolisib, a precision oncology drug, for men with metastatic castration-resistant prostate cancer (mCRPC).. The InavoPC trial offers a distinct approach: combining a PI3K inhibitor with continued hormonal therapy to address a fundamental biological mechanism of treatment resistance. Inavolisib is a highly selective inhibitor of the PI3Kα kinase enzyme. […]
GVV858 is a CDK2 inhibitor designed to block this escape route. Instead of adding another hormone therapy when resistance develops, it targets the cell cycle machinery that CCNE1-amplified tumors depend on. The drug works on the molecular brakes that control when cells divide, rather than trying to manipulate hormone levels further. CCNE1 amplification allows cancer […]
AB-3028, programmable circuit T cell therapy for metastatic castration-resistant prostate cancer (mCRPC), has now advanced into a Phase 1/2 clinical trial. This marks the first clinical testing of this highly engineered, logic‑gated CAR-T platform in prostate cancer, moving it from a purely preclinical concept into human evaluation. The trial should start recruiting in January 2026. […]
A research from Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine shows that prostate cancer cells can synthesize androgens through an alternative pathway that does not rely on CYP17A1, the enzyme at the core of virtually all modern androgen deprivation strategies. Instead of flowing through the classical cholesterol → pregnenolone […]
A new drug called AO-252, an oral inhibitor of TACC3, is now in phase 1 trials specifically testing it against prostate cancer among other solid tumors. It smartly blocks TACC3’s key partnerships with proteins like KIFC1, clathrin, BRCA1, and others, triggering mitotic disasters and halting growth in both lab models and early patients (some saw tumors […]